Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

NCT ID: NCT06589804Sponsor: National Cancer Institute (NCI)Last updated: 2026-06-11

Summary

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary site) to other places in the body (metastatic). Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving cetuximab and pembrolizumab together may be more effective at treating patients with recurrent and/or metastatic HNSCC than pembrolizumab alone.

Detailed description

PRIMARY OBJECTIVE: I. To assess whether the combination of cetuximab and pembrolizumab (arm 2) compared to pembrolizumab alone (arm 1) results in improved overall survival (OS) in subjects with platinum refractory HNSCC. SECONDARY OBJECTIVES: I. To compare pembrolizumab + cetuximab (arm 2) versus (vs.) pembrolizumab alone (arm 1) with respect to objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. II. To compare pembrolizumab + cetuximab (arm 2) vs. pembrolizumab alone (arm 1) with respect to progression free survival (PFS) per RECIST 1.1. III. To evaluate pembrolizumab + cetuximab (arm 2) vs. pembrolizumab alone (arm 1) with respect to duration of response (DOR) per RECIST 1.1. IV. To assess the safety and tolerability of pembrolizumab + cetuximab (arm 2) vs. pembrolizumab alone (arm 1). V. To assess the patient-reported toxicity using Patient Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) of pembrolizumab + cetuximab (arm 2) vs. pembrolizumab alone (arm 1). EXPLORATORY OBJECTIVES: I. To identify specific mutational changes that may be indicative of clinical response to pembrolizumab + cetuximab and pembrolizumab alone. II. To evaluate circulating tumor-derived deoxyribonucleic acid (ctDNA) kinetics over the course of treatment in response to pembrolizumab + cetuximab and pembrolizumab alone. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), positron emission tomography (PET)/CT or magnetic resonance imaging (MRI) throughout the trial and optionally undergo blood sample collection on study and at disease progression or end of treatment. ARM 2: Patients receive cetuximab IV over 120 minutes on day -14 prior to cycle 1 and then on days 1, 15 and 29 of each cycle and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT or MRI throughout the trial and optionally undergo blood sample collection on study and at disease progression or end of treatment. After completion of study treatment, patients are followed up within 4 weeks and then every 3 and/or 6 months for up to 5 years.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • BiologicalCetuximab

    Given IV

  • ProcedureComputed Tomography

    Undergo CT or PET/CT

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

  • BiologicalPembrolizumab

    Given IV

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

Outcome measures

Primary

  • Overall survival (OS)

    Will be estimated using the Kaplan-Meier method. Will be based on the stratified log-rank test that will compare the distributions across the treatment arms. Univariable and multivariable Cox models stratified by the stratification factors used in the randomization will be assessed as well, where the multivariable Cox model will also adjust for other key baseline factors of interest. Hazard ratios and 95% confidence intervals, along with likelihood ratio p-values will be reported from these Cox models.

    Time frame: Time from randomization to death from any cause, assessed up to 5 years

Secondary

  • Confirmed response rate

    Time frame: Up to 5 years

  • Duration of response

    Time frame: From the date at which the patient's earliest best objective status is first noted to be either a complete response or partial response to the earliest date progression is documented, assessed up to 5 years

  • Progression free survival

    Time frame: Time from randomization to the first of either disease progression or death from any cause, assessed up to 5 years

  • Incidence of adverse events

    Time frame: Up to 5 years

  • Patient-reported toxicity

    Time frame: Up to 5 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Histologically confirmed diagnosis head and neck squamous cell carcinomas (HNSCC). * Previously untreated for recurrent and/or metastatic disease incurable by local therapies. * Primary tumor location of oral cavity, oropharynx, larynx, or hypopharynx. * Note: Other primary tumor sites of HNSCC, including nasopharynx primary tumor are not eligible. Unknown primary tumors may be eligible and can be enrolled at the discretion of the treatment team with approval by the study chair. * Measurable disease. * Must have platinum-refractory disease defined as disease progression during or ≤ 29 weeks after completion of definitive therapy (chemoradiation therapy) or adjuvant (post-operative) therapy. * Patient must have a combined positive score PD-L1 positive (CPS \>/= 1) tumor. * Any radiation therapy must be completed \>= 10 days prior to registration. * Patients should not have received any prior treatment in the recurrent or metastatic setting. * Prior therapy with neoadjuvant or induction anti PD-1/PD-L1 monoclonal antibody or cetuximab in the curative setting is allowed if last treatment dose was \>= 26 weeks prior to registration without evidence of disease progression during that treatment period. * Patient has not received a live vaccine within 30 days prior to registration. * Patient does not have a history of any contraindication or has a severe hypersensitivity to any component of pembrolizumab or cetuximab (≥ grade 3). * Patient has not received chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration. * Patient with oropharyngeal cancer only must have negative results from testing of human papillomavirus (HPV) status defined as p16 immunohistochemistry (IHC) and/or HPV in situ hybridization (ISH). * Note: A Clinical Laboratory Improvement Act (CLIA) certified circulating tumor HPV deoxyribonucleic acid (ctHPVDNA) assay can be used if tissue sample is not available. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3. * Platelet count ≥ 100,000/mm\^3. * Hemoglobin (Hgb) ≥ 9 g/dL (if \< 9 g/dL, then transfusions are acceptable to increase hemoglobin above 9 g/dL). * Creatinine ≤ 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula for participant with creatinine levels \> 1.5 x institutional ULN. * Total bilirubin ≤ 1.5 x ULN OR direct bilirubin \< ULN for participant with total bilirubin \> 1.5 x institutional ULN. * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \[SGPT\]) ≤ 3.0 x ULN unless liver metastases are present in which case \< 5.0 x ULN. * Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. * Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 7 days prior to registration is required. * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included. * For treated/stable brain metastases: Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. * Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. * Patients does not have a history of active myocarditis. * Patients does not have a history of any form of pneumonitis or diffuse idiopathic or immune mediated interstitial pulmonary disease. * Patient does not have a history of solid organ transplantation.

Study locations (177)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205

Recruiting
Site Public Contact · Contact
501-686-8274
Omar T. Atiq · Principal Investigator

Fremont - Rideout Cancer Center

Marysville, California, 95901

Terminated

VA Palo Alto Health Care System

Palo Alto, California, 94304

Suspended

UCHealth Memorial Hospital Central

Colorado Springs, Colorado, 80909

Recruiting
Site Public Contact · Contact
719-365-2406
Steven R. Schuster · Principal Investigator

Memorial Hospital North

Colorado Springs, Colorado, 80920

Recruiting
Site Public Contact · Contact
719-364-6700
Steven R. Schuster · Principal Investigator

Poudre Valley Hospital

Fort Collins, Colorado, 80524

Recruiting
Site Public Contact · Contact
970-297-6150
Steven R. Schuster · Principal Investigator

Cancer Care and Hematology-Fort Collins

Fort Collins, Colorado, 80528

Recruiting
Site Public Contact · Contact
773-702-9171protocols@AllianceNCTN.org
Steven R. Schuster · Principal Investigator

Lutheran Hospital - Cancer Centers of Colorado

Golden, Colorado, 80401

Recruiting
Site Public Contact · Contact
peaksresearch@imail.org
Karng S. Log · Principal Investigator

UCHealth Greeley Hospital

Greeley, Colorado, 80631

Recruiting
Site Public Contact · Contact
773-702-9171protocols@AllianceNCTN.org
Steven R. Schuster · Principal Investigator

Medical Center of the Rockies

Loveland, Colorado, 80538

Recruiting
Site Public Contact · Contact
970-203-7083
Steven R. Schuster · Principal Investigator

Mount Sinai Medical Center

Miami Beach, Florida, 33140

Recruiting
Site Public Contact · Contact
305-674-2625Yvonne.Enriquez@msmc.com
Mike Cusnir · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Christopher M. Reynolds · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Advocate Good Shepherd Hospital

Barrington, Illinois, 60010

Recruiting
Site Public Contact · Contact
847-842-4847
Peter J. Polewski · Principal Investigator

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Ari J. Rosenberg · Principal Investigator

Advocate Illinois Masonic Medical Center

Chicago, Illinois, 60657

Recruiting
Site Public Contact · Contact
773-296-5360
Peter J. Polewski · Principal Investigator

AMG Crystal Lake - Oncology

Crystal Lake, Illinois, 60014

Recruiting
Site Public Contact · Contact
630-929-6129advocateresearch@advocate.com
Peter J. Polewski · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Advocate Good Samaritan Hospital

Downers Grove, Illinois, 60515

Recruiting
Site Public Contact · Contact
630-275-1270Barbara.barhamand@advocatehealth.com
Peter J. Polewski · Principal Investigator

Crossroads Cancer Center

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Advocate Sherman Hospital

Elgin, Illinois, 60123

Recruiting
Site Public Contact · Contact
847-429-2907
Peter J. Polewski · Principal Investigator

Advocate South Suburban Hospital

Hazel Crest, Illinois, 60429

Recruiting
Site Public Contact · Contact
708-799-9995
Peter J. Polewski · Principal Investigator

AMG Libertyville - Oncology

Libertyville, Illinois, 60048

Recruiting
Site Public Contact · Contact
630-929-6129advocateresearch@advocatehealth.com
Peter J. Polewski · Principal Investigator

Condell Memorial Hospital

Libertyville, Illinois, 60048

Recruiting
Site Public Contact · Contact
630-929-6129advocateresearch@advocatehealth.com
Peter J. Polewski · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UC Comprehensive Cancer Center at Silver Cross

New Lenox, Illinois, 60451

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Ari J. Rosenberg · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699

Recruiting
Site Public Contact · Contact
800-323-8622
Peter J. Polewski · Principal Investigator

Advocate Outpatient Center - Oak Lawn

Oak Lawn, Illinois, 60453

Recruiting
Site Public Contact · Contact
ncorp@aah.org
Peter J. Polewski · Principal Investigator

University of Chicago Medicine-Orland Park

Orland Park, Illinois, 60462

Recruiting
Site Public Contact · Contact
773-702-8222cancerclinicaltrials@bsd.uchicago.edu
Ari J. Rosenberg · Principal Investigator

Advocate High Tech Medical Park

Palos Heights, Illinois, 60463

Recruiting
Site Public Contact · Contact
ncorp@aah.org
Peter J. Polewski · Principal Investigator

Advocate Lutheran General Hospital

Park Ridge, Illinois, 60068

Recruiting
Site Public Contact · Contact
847-384-3621
Peter J. Polewski · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UW Health Carbone Cancer Center Rockford

Rockford, Illinois, 61114

Recruiting
Site Public Contact · Contact
779-696-9378lkline@uwhealth.org
Fahrettin Covut · Principal Investigator

Memorial Hospital East

Shiloh, Illinois, 62269

Recruiting
Site Public Contact · Contact
314-747-9912dschwab@wustl.edu
Christine Auberle · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

UChicago Medicine Northwest Indiana

Crown Point, Indiana, 46307

Recruiting
Site Public Contact · Contact
855-702-8222cancerclinicaltrials@bsd.uchicago.edu
Ari J. Rosenberg · Principal Investigator

Mary Greeley Medical Center

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Ames

Ames, Iowa, 50010

Recruiting
Site Public Contact · Contact
515-239-4734ksoder@mcfarlandclinic.com
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Boone

Boone, Iowa, 50036

Suspended

Mercy Hospital

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-365-4673
Deborah W. Wilbur · Principal Investigator

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-363-2690
Deborah W. Wilbur · Principal Investigator

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

Suspended

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

Recruiting
Site Public Contact · Contact
515-956-4132
Joseph J. Merchant · Principal Investigator

HaysMed

Hays, Kansas, 67601

Recruiting
Site Public Contact · Contact
785-623-5774
Prakash C. Neupane · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

Recruiting
Site Public Contact · Contact
785-505-2800Stephanie.Norris@LMH.ORG
Prakash C. Neupane · Principal Investigator

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

Recruiting
Site Public Contact · Contact
913-588-1569OlatheCCResearch@kumc.edu
Prakash C. Neupane · Principal Investigator

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

Salina Regional Health Center

Salina, Kansas, 67401

Recruiting
Site Public Contact · Contact
785-452-7038mleepers@srhc.com
Prakash C. Neupane · Principal Investigator

University of Kansas Health System Saint Francis Campus

Topeka, Kansas, 66606

Recruiting
Site Public Contact · Contact
785-295-8000
Prakash C. Neupane · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201

Recruiting
Site Public Contact · Contact
800-888-8823
Ranee Mehra · Principal Investigator

Boston Medical Center

Boston, Massachusetts, 02118

Recruiting
Site Public Contact · Contact
617-638-8265
Peter C. Everett · Principal Investigator

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Christopher M. Reynolds · Principal Investigator

Genesee Hematology Oncology PC

Flint, Michigan, 48503

Suspended

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Christopher M. Reynolds · Principal Investigator

Hurley Medical Center

Flint, Michigan, 48503

Recruiting
Site Public Contact · Contact
810-762-8038wstrong@ghci.org
Christopher M. Reynolds · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Mercy Hospital

Coon Rapids, Minnesota, 55433

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Fairview Southdale Hospital

Edina, Minnesota, 55435

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Daniel M. Anderson · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Christine Auberle · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Christine Auberle · Principal Investigator

University Health Truman Medical Center

Kansas City, Missouri, 64108

Recruiting
Site Public Contact · Contact
816-404-4375
Prakash C. Neupane · Principal Investigator

University of Kansas Cancer Center - Briarcliff

Kansas City, Missouri, 64116

Recruiting
Site Public Contact · Contact
913-588-3671
Prakash C. Neupane · Principal Investigator

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Prakash C. Neupane · Principal Investigator

Lake Regional Hospital

Osage Beach, Missouri, 65065

Recruiting
Site Public Contact · Contact
573-302-2768clinicaltrials@lakeregional.com
Jay W. Carlson · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Christine Auberle · Principal Investigator

Mercy Hospital South

St Louis, Missouri, 63128

Recruiting
Site Public Contact · Contact
314-525-6042Danielle.Werle@mercy.net
Jay W. Carlson · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Christine Auberle · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Christine Auberle · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@dartmouth.edu
Joerg Rathmann · Principal Investigator

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Jefferson Cherry Hill Hospital

Cherry Hill, New Jersey, 08002

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jeffrey A. Stevens · Principal Investigator

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Sidney Kimmel Cancer Center Washington Township

Sewell, New Jersey, 08080

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jeffrey A. Stevens · Principal Investigator

Memorial Sloan Kettering Commack

Commack, New York, 11725

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Glens Falls Hospital

Glens Falls, New York, 12801

Recruiting
Site Public Contact · Contact
518-926-6700
Aqeel A. Gillani · Principal Investigator

Memorial Sloan Kettering Westchester

Harrison, New York, 10604

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

State University of New York Upstate Medical University

Syracuse, New York, 13210

Recruiting
Site Public Contact · Contact
315-464-5476
Komal Akhtar · Principal Investigator

SUNY Upstate Medical Center-Community Campus

Syracuse, New York, 13215

Recruiting
Site Public Contact · Contact
315-464-5476
Komal Akhtar · Principal Investigator

Memorial Sloan Kettering Nassau

Uniondale, New York, 11553

Recruiting
Site Public Contact · Contact
212-639-7592
Alan L. Ho · Principal Investigator

Upstate Cancer Center at Verona

Verona, New York, 13478

Recruiting
Site Public Contact · Contact
315-464-8230McDowelE@upstate.edu
Komal Akhtar · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Siddharth Sheth · Principal Investigator

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, 28791

Recruiting
Site Public Contact · Contact
828-696-4716pardeecancerresearch@unchealth.unc.edu
John K. Hill · Principal Investigator

FirstHealth of the Carolinas-Moore Regional Hospital

Pinehurst, North Carolina, 28374

Recruiting
Site Public Contact · Contact
910-715-3500jcwilliams@firsthealth.org
Charles S. Kuzma · Principal Investigator

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Miami Valley Hospital South

Centerville, Ohio, 45459

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Tarek M. Sabagh · Principal Investigator

Miami Valley Hospital

Dayton, Ohio, 45409

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Tarek M. Sabagh · Principal Investigator

Miami Valley Hospital North

Dayton, Ohio, 45415

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Tarek M. Sabagh · Principal Investigator

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Tarek M. Sabagh · Principal Investigator

Miami Valley Cancer Care and Infusion

Greenville, Ohio, 45331

Recruiting
Site Public Contact · Contact
937-569-7515
Tarek M. Sabagh · Principal Investigator

ProMedica Flower Hospital

Sylvania, Ohio, 43560

Recruiting
Site Public Contact · Contact
419-824-1842PCIOncResearch@promedica.org
Chang Xia · Principal Investigator

Upper Valley Medical Center

Troy, Ohio, 45373

Recruiting
Site Public Contact · Contact
937-528-2900clinical.trials@daytonncorp.org
Tarek M. Sabagh · Principal Investigator

Cancer Centers of Southwest Oklahoma Research

Lawton, Oklahoma, 73505

Recruiting
Site Public Contact · Contact
877-231-4440
Minh Phan · Principal Investigator

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Recruiting
Site Public Contact · Contact
405-271-8777ou-clinical-trials@ouhsc.edu
Minh Phan · Principal Investigator

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Christopher M. Reynolds · Principal Investigator

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Christopher M. Reynolds · Principal Investigator

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Christopher M. Reynolds · Principal Investigator

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

Recruiting
Site Public Contact · Contact
610-402-9543Morgan_M.Horton@lvhn.org
Christopher M. Reynolds · Principal Investigator

Jefferson Torresdale Hospital

Philadelphia, Pennsylvania, 19114

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Jeffrey A. Stevens · Principal Investigator

Medical University of South Carolina

Charleston, South Carolina, 29425

Recruiting
Site Public Contact · Contact
843-792-9321hcc-clinical-trials@musc.edu
John M. Kaczmar · Principal Investigator

Avera Cancer Institute - Mitchell

Mitchell, South Dakota, 57301

Recruiting
Site Public Contact · Contact
605-322-3096OncRegulatory@avera.org
Benjamin M. Solomon · Principal Investigator

Avera Cancer Institute at Pierre

Pierre, South Dakota, 57501

Recruiting
Site Public Contact · Contact
605-322-3095OncRegulatory@avera.org
Benjamin M. Solomon · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicTrialsSF@sanfordhealth.org
Daniel Almquist · Principal Investigator

Avera Cancer Institute

Sioux Falls, South Dakota, 57105

Recruiting
Site Public Contact · Contact
605-322-3095OncRegulatory@avera.org
Benjamin M. Solomon · Principal Investigator

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Daniel Almquist · Principal Investigator

Avera Cancer Institute at Yankton

Yankton, South Dakota, 57078

Recruiting
Site Public Contact · Contact
605-655-1800OncRegulatory@avera.org
Benjamin M. Solomon · Principal Investigator

Dartmouth Cancer Center - North

Saint Johnsbury, Vermont, 05819

Recruiting
Site Public Contact · Contact
800-639-6918cancer.research.nurse@hitchcock.org
Joerg Rathmann · Principal Investigator

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, 23235

Recruiting
Site Public Contact · Contact
ctoclinops@vcu.edu
Erin R. Alesi · Principal Investigator

VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298

Recruiting
Site Public Contact · Contact
804-628-6430CTOclinops@vcu.edu
Erin R. Alesi · Principal Investigator

West Virginia University Charleston Division

Charleston, West Virginia, 25304

Recruiting
Site Public Contact · Contact
304-388-9944
Kok Hoe Chan · Principal Investigator

Aurora Cancer Care-Southern Lakes VLCC

Burlington, Wisconsin, 53105

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Saint Luke's South Shore

Cudahy, Wisconsin, 53110

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Marshfield Medical Center-EC Cancer Center

Eau Claire, Wisconsin, 54701

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Seth O. Fagbemi · Principal Investigator

Aurora Health Care Germantown Health Center

Germantown, Wisconsin, 53022

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Cancer Care-Grafton

Grafton, Wisconsin, 53024

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Cancer Care-Kenosha South

Kenosha, Wisconsin, 53142

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
Michael O. Ojelabi · Principal Investigator

Aurora Bay Area Medical Group-Marinette

Marinette, Wisconsin, 54143

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Marshfield Medical Center-Marshfield

Marshfield, Wisconsin, 54449

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Seth O. Fagbemi · Principal Investigator

Aurora Cancer Care-Milwaukee

Milwaukee, Wisconsin, 53209

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Saint Luke's Medical Center

Milwaukee, Wisconsin, 53215

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53233

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Recruiting
Site Public Contact · Contact
research.institute@phci.org
Timothy R. Wassenaar · Principal Investigator

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Recruiting
Site Public Contact · Contact
262-928-7878
Timothy R. Wassenaar · Principal Investigator

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora Cancer Care-Racine

Racine, Wisconsin, 53406

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan, Wisconsin, 53081

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Marshfield Medical Center-River Region at Stevens Point

Stevens Point, Wisconsin, 54482

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Seth O. Fagbemi · Principal Investigator

Aurora Medical Center in Summit

Summit, Wisconsin, 53066

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers, Wisconsin, 54241

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

ProHealth Waukesha Memorial Hospital

Waukesha, Wisconsin, 53188

Recruiting
Site Public Contact · Contact
262-928-7632
Timothy R. Wassenaar · Principal Investigator

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

Recruiting
Site Public Contact · Contact
262-928-5539Chanda.miller@phci.org
Timothy R. Wassenaar · Principal Investigator

Aurora Cancer Care-Milwaukee West

Wauwatosa, Wisconsin, 53226

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Aurora West Allis Medical Center

West Allis, Wisconsin, 53227

Recruiting
Site Public Contact · Contact
414-302-2304ncorp@aurora.org
Peter J. Polewski · Principal Investigator

Marshfield Medical Center - Weston

Weston, Wisconsin, 54476

Recruiting
Site Public Contact · Contact
800-782-8581oncology.clinical.trials@marshfieldresearch.org
Seth O. Fagbemi · Principal Investigator